Kenvue (KVUE) to Release Earnings on Tuesday

Kenvue (NYSE:KVUE) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Kenvue to post earnings of $0.26 per share for the quarter. Kenvue has set its FY guidance at $1.10-1.20 EPS and its FY 2024 guidance at 1.100-1.200 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. The business’s revenue was down 2.7% on a year-over-year basis. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Performance

NYSE KVUE opened at $19.20 on Friday. The company has a fifty day simple moving average of $19.82 and a 200 day simple moving average of $20.12. Kenvue has a 12-month low of $17.82 and a 12-month high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on KVUE shares. JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Sanford C. Bernstein started coverage on shares of Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. Royal Bank of Canada cut their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. The Goldman Sachs Group started coverage on shares of Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Finally, William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.